Transcriptome Sequencing Analysis of the Effect of β-Elemene on Colorectal Cancer from the lncRNA-miRNA-mRNA Perspective

Heng Deng,1 Shuo Chen,2 Xiancang Yuan,3 and Jun Zhang4

1Department of Anorectal Surgery, Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China
2The Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China
3Department of Anorectal Surgery, Huainan City First People’s Hospital, Huainan, China
4Chinese Medicine Teaching and Research Section, Anhui University of Chinese Medicine, Hefei, China

Correspondence should be addressed to Jun Zhang; zhangjun98765432@163.com

Received 24 June 2022; Revised 18 August 2022; Accepted 22 August 2022; Published 13 September 2022

Object. β-Elemene is an emerging antitumor Chinese medicine, but the exact mechanism of action of β-elemene in colorectal cancer (CRC) remains unclear. This study aimed to explore the mechanism of the lncRNA-miRNA-mRNA network in the process of β-elemene inhibiting CRC.

Methods. RNA sequencing was performed on CRC cells from the control group (untreated) and the case group (β-elemene-treated). According to the sequencing data, we screened the differentially expressed (DE) lncRNAs, miRNAs, and mRNAs and then analyzed them by functional enrichment analyses. Through the lncRNA-miRNA-mRNA network, the key miRNAs and mRNAs involved in the process of β-elemene inhibiting CRC were further identified.

Results. Totally, 607 upregulated and 599 downregulated DElncRNAs, 12 downregulated and 24 upregulated DEMiRNAs, and 3153 downregulated and 3248 upregulated DEMRNAs were identified. Through the lncRNA-miRNA-mRNA network, 3 miRNAs (miR-7109-3p, miR-4506, and miR-3182), 7 prognostic mRNAs (ALPG, DTX1, HOXD13, RIMS3, SLC16A8, SYT1, and TNNT1), and 2 key mRNAs (RIMS3 and SLC16A8) were determined to participate in the inhibitory mechanism of β-elemene in CRC.

Conclusion. This study revealed for the first time that the lncRNA-miRNA-mRNA network is involved in the regulation of β-elemene in CRC, and these identified miRNAs and mRNAs could be new clinical prognostic biomarkers and therapeutic targets for CRC patients.

1. Background

Colorectal cancer (CRC) is a kind of disease with an increased morbidity year by year [1]. Many factors may contribute to the incidence of CRC, including genetics, environment, colon polyp, diet habits, and so on [2, 3]. Bloody stool is usually the earliest and commonest symptom of CRC. When it comes to the advanced stage, there will be anemia, acute peritonitis, tumor metastasis, and so on [3, 4]. In the recent 50 years, although much progress has been made in medical conditions, the 5 years survival rate of CRC still hovers around 50% due to its high recurrence [5]. At present, it is still important to explore new, safe, and effective treatment options for CRC patients.

In recent years, studies have shown that RNA with different lengths interacts with each other, especially among microRNA (miRNA), long noncoding RNA (lncRNA), and messenger RNA (mRNA), thus forming a mutual regulatory network of lncRNA-miRNA-mRNA that is important to show the interactions between RNA molecules and explain their functions [6–8]. With relatively high specificity in cells and tissues and a wide existence in various human tissues from serum and stool, miRNAs are good noninvasive biological agents for the measurement of precancerous and cancerous lesions and therapeutic targets in many diseases [9, 10]. Thus, searching for miRNAs in CRC progression and its mRNA targets could be a method to find more effective diagnostic biomarkers and treatment targets for CRC.
Figure 1: Continued.
patients. Previously, some researchers analyzed the correlation between abnormally expressed miRNAs and CRC by constructing a differential miRNA bioinformatics expression map and predicted that it would affect CRC by interfering with downstream signaling pathways [11].

β-Elemene is a bioactive compound extracted from natural plants. As an emerging antitumor Chinese medicine, β-elemene has been applied in medical therapies because it could boost the effects of other antitumor Chinese medicines on lung cancer [12], breast cancer [13], colorectal cancer [14], glioma [15], osteosarcoma [16], and so on and decrease the side effects of radiotherapy and chemotherapy [17]. Previously, Chen P et al. found that by triggering ferroptosis and suppressing EMT, the β-elemene and cetuximab therapies were sensitive to KRAS-mutated CRC cells [14]. LQ_he other report indicates that β-elemene could suppress the occurrence and development of CRC in the nude mouse by affecting transplanted tumor proliferation, apoptosis, and autophagy process [18]. However, the exact mechanism between β-elemene and CRC has not been studied yet. Therefore, we intend to analyze the regulatory lncRNA-miRNA-mRNA mechanism of β-elemene-miRNA-mRNA in CRC by whole quasi-transcriptome sequencing.

2. Materials and Methods

2.1. Cell Culture and Treatment. The HCT-116 cells were from the China National Collection of Authenticated Cell Culture (Shanghai, China). The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) obtained from Carlsbad, CA, USA, with 2 ml glutamine and 10% Fetal bovine serum (FBS) obtained from Gibco, USA, in a humidified environment with 5% CO2 at 37°C. β-Elemene is available from Sigma. Cells treated with β-elemene were further used for RNA sequencing.

2.2. Small RNA Sequencing. We selected the control (no treatment) and case groups (β-elemene treatment) for RNA sequencing and pertinent analysis. Then, the RNA sequencing was performed by Origin-Biotech Inc. (Shanghai, China).

2.3. Identification of Differentially Expressed (DE) lncRNA, miRNA, and mRNA. Based on the RNA sequencing data, DElncRNA, DEMiRNA, and DEMRNA were identified by edgeR with a threshold of \( P < 0.05 \) and the absolute values of \( |\log_2 \text{fold change (FC)}| > 1 \), respectively.

2.4. Functional Enrichment Analysis on the DElncRNA, DEMiRNA, and DEMRNA. Gene Ontology (GO) contains a set of related terms or concepts, and it describes the understanding of biology from three domains: cellular
component (CC), biological process (BP), and molecular function (MF). The Kyoto Encyclopedia of Gene and Genome (KEGG) is a predictive calculation tool on the basis of relevant knowledge. Given a complete set of genes on a chromosome, it can anticipate the relevance of protein interaction networks in a variety of biological functions. Herein, the R package (v 3.5.1) and clusterProfiler were applied for this analysis.

2.5. Protein-Protein-Interaction (PPI) Network on the DElncRNA, DEmiRNA, and DEMRNA. Then, the Search Tool for the Retrieval of Interacting Genes (STRING v 11.5, https://cn.string-db.org/) tool was adopted to map PPI networks for all DElncRNA, DEmiRNA, and DEmRNA with a composite interaction score $\geq 0.4$. Cytoscape was adopted to visualize the PPI networks. Herein, connectivity among DElncRNA ($n = 10$), DEmiRNA ($n = 3$), and DEmRNA ($n = 53$) with high degrees was demonstrated by an independent PPI network.

2.6. The LASSO Analysis and Prognostic Signature Model Construction on the above 53 DEmRNAs. After the screening of the top 53 DEmRNAs from the sequencing data of $\beta$-elemene-treated CRC cells, we performed the least absolute shrinkage and selection operator (LASSO) regression model by the “glmnet” package of the R language. The relationship between the partial likelihood deviation and log ($\lambda$) was plotted, and the important parameters of the signature model were obtained. Moreover, we downloaded clinical samples of CRC from the Cancer and Genome Atlas (TCGA, https://tcga-data.nci.nih.gov/tcga) dataset and analyzed the prognostic values of mRNAs in clinical. First, CRC samples were classified into high-risk ($n = 309$) and low-risk ($n = 310$) groups in the risk score analysis, and the

| Table 1: Top 5 increased and decreased DElncRNAs. |
|-------------------------------------------------|
| Gene ID | Transcript | Gene name | Status | P value   |
|---------|------------|-----------|--------|-----------|
| ENSG00000225791 | ENST00000667019 | TRAM2 | Increased | 1.12E-09 |
| ENSG00000285517 | ENST00000649390 | Novel gene | Increased | 2.35E-08 |
| ENSG00000271853 | ENST00000497086 | Novel gene | Increased | 5.04E-06 |
| ENSG00000258525 | ENST00000661204 | Novel gene | Increased | 1.64E-10 |
| ENSG00000179818 | ENST00000654878 | PCBP1 | Increased | 5.46E-08 |

| Table 2: Top 5 increased and decreased DEmiRNAs. |
|------------------------------------------------|
| miRNA | Status | logFC   | P value    |
|-------|--------|---------|------------|
| hsa-miR-6773-3p | Increased | 3.61676331 | 0.002245373 |
| hsa-miR-1250-3p | Increased | 3.379810682 | 0.002053361 |
| hsa-miR-6848-5p | Increased | 2.780991902 | 0.00707793 |
| hsa-miR-4506 | Increased | 2.226485819 | 8.45E-06 |
| hsa-miR-7109-3p | Increased | 2.184563759 | 0.034727373 |

| Table 3: Top 5 increased and decreased DEmRNAs. |
|------------------------------------------------|
| Gene ID | Transcript | Gene name | Status | P value   |
|---------|------------|-----------|--------|-----------|
| ENSG00000129657 | ENST00000430767 | SECI4L1 | Increased | 6.56E-20 |
| ENSG00000144580 | ENST00000542068 | CNOT9 | Increased | 1.13E-11 |
| ENSG00000161016 | ENST00000533397 | RPL8 | Increased | 3.45E-09 |
| ENSG00000149782 | ENST00000325234 | PLCB3 | Increased | 7.20E-30 |
| ENSG00000145425 | ENST00000512690 | RPS3A | Increased | 1.55E-24 |
| ENSG00000084774 | ENST00000403525 | CAD | Decreased | 1.34E-33 |
| ENSG00000167881 | ENST00000539137 | SRP68 | Decreased | 7.75E-12 |
| ENSG00000124532 | ENST00000274747 | MRS2 | Decreased | 2.38E-19 |
| ENSG00000197713 | ENST00000354506 | RPE | Decreased | 1.61E-11 |
| ENSG00000254093 | ENST00000519088 | PINX1 | Decreased | 2.39E-18 |

https://doi.org/10.1155/2022/5896296 Published online by Cambridge University Press
Brain-derived neurotrophic factor (BDNF) signaling pathway WP304
ncRNAs involved in STAT3 signaling in hepatocellular carcinoma WP2380
Positive regulation of muscle hyperplasia
Regulation of cell activation
Lung growth
Growth arrest by miRNA
Negative regulation of cell-cell adhesion
Regulation of cell differentiation
Cardiac right ventricle morphogenesis
Negative regulation of cardiac muscle cell proliferation
ncRNA binding involved in posttranscriptional gene silencing

(a)
(b)
(c)
(d)
(e)
(f)

Figure 2: The GO and KEGG enrichment analyses on DElncRNAs, DEmiRNAs, and DEmRNAs. (a) The GO analysis of IncRNAs. (b) The KEGG pathway enrichment analysis of IncRNAs. (c) The GO analysis of miRNAs. (d) The KEGG pathway enrichment analysis of miRNAs. (e) The GO analysis of mRNAs. (f) The KEGG pathway enrichment analysis of mRNAs.
survival status of CRC samples corresponding to 15 different mRNAs was displayed. Next, the overall survival (OS) probability between two groups was compared by the Kaplan–Meier (KM, https://kmplot.com/analysis/) survival curve. Finally, the receiver operating characteristic (ROC) curve was used to compare the area under the curve (AUC) values of 1-, 3-, and 5-year survival rates of CRC, and the HR with 95% CI was calculated.

2.7. The Establishment of Prognostic Nomogram in CRC. To further verify the key mRNAs on the prognosis of CRC patients, the “forestplot” package was used to draw forest plots to display the results of univariate and multivariate Cox regression analyses on the above 15 mRNAs, and the corresponding P value and hazard ratio (HR) with 95% CI were calculated. Then, 7 mRNAs related to CRC prognosis were identified. Then, the corresponding nomogram was constructed by the “rms” package to predict the 1-, 3-, and 5-year survival rates with 7 prognostic mRNAs for CRC patients. The closer the dots are to the calibration curve, the higher the accuracy of this nomogram.

2.8. The Expression Verification and KM Analysis on the 7 Prognostic mRNAs. Based on the above findings, we detected their expressions in CRC tumor (n = 620) and normal (n = 10) samples in the TCGA database to identify the key mRNAs related to CRC. Then, the relations between the key mRNA expressions and OS and progression-free survival (PFS) curves were studied.

3. Results

3.1. DElncRNA, DEmiRNA, and DEmRNA from β-Elemene-Treated Samples. First, we analyzed the DElncRNA, DEmiRNA, and DEmRNA expression profiling data from β-elemene-treated samples. According to the RNA-seq analysis, 607 upregulated and 599 downregulated DElncRNAs were identified and displayed by volcano and heat maps (Figures 1(a) and 1(b)), and the top 5 upregulated and downregulated DElncRNAs are demonstrated in Table 1. As shown in Figures 1(c) and 1(d), we identified 12 downregulated and 24 upregulated DEmiRNAs, and the top 5 of each group are shown in Table 2. Besides, 3153 downregulated and 3248 upregulated DEmRNAs are displayed in Figures 1(e) and 1(f), and the top 5 DEmRNAs of them are also shown in Table 3.

3.2. The Results of GO Term and KEGG Pathway Enrichment Analyses. In GO analysis, DElncRNAs were enriched in positive regulation of muscle hyperplasia, regulation of B cell activation, lung growth (BP), and mRNA binding involved in posttranscriptional gene silencing (MF, Figure 2(a)). DEmiRNAs were enriched in negative regulation of transcription by RNA polymerase II, positive regulation of gene expression (BP), transcription regulator complex, chromatin, heteromeric SMAD protein complex (CC), DNA-binding transcription factor binding, and sequence-specific DNA binding (MF, Figure 2(c)). DEmRNAs were enriched in positive regulation of phospholipase C activity (BP), basolateral plasma membrane (CC), clathrin-coated vesicle membrane, and RNA polymerase III complex (MF, Figure 2(e)). In the KEGG pathway analysis, DElncRNAs were related to the CCL18 signaling pathway, ncRNAs in involved in STAT3 signaling in hepatocellular carcinoma, IncRNA mediated mechanisms of therapeutic resistance (Figure 2(b)), DEmiRNAs were related to the integrated breast cancer pathway, the TGF-beta signaling pathway, senescence, and autophagy in cancer (Figure 2(d)), and
Figure 4: Continued.
DEmRNAs were related to the ectoderm differentiation, the leptin signaling pathway, and so on (Figure 2(f)).

3.3. The IncRNA-miRNA-mRNA Coexpression Network Analysis. Next, we constructed a PPI network of the DERNAs with the Cytoscape tool (Figure 3(a)). According to the degrees in each group, DERNAs with high degrees (composite interaction score $\geq 0.4$) in each group were selected for the construction of the IncRNA-miRNA-mRNA network, including 10 DElncRNAs, 3 DEmiRNAs, and 53 DEDmRNAs. As demonstrated in Figure 3(b), miR-7109-3p, miR-4506, and miR-3182 were closely related to ambient DElncRNAs and DEmRNAs, which indicated that miR-7109-3p, miR-4506, and miR-3182 had the potential to be clinical biomarkers or therapeutic targets in CRC.

Nodes represent genes, and edges represent interactions between genes. The green nodes represent the IncRNA, the red nodes represent the miRNA, and the purple nodes represent the mRNA.

3.4. The LASSO Analysis and Prognostic Signature Model Construction of the 53 DEmRNAs. The LASSO regression analysis was first performed on the above 53 DEmRNAs to determine the optimal parameter number of the signature model (Figures 4(a) and 4(b), each line represented a DEmRNA). Then, CRC samples in the TCGA database were divided into high-risk (n = 309) and low-risk groups (n = 310),
| Uni_cox | P value | Hazard Ratio (95%CI) |
|---------|---------|---------------------|
| ALPG    | 4e–04   | 1.16343 (1.06988, 1.26516) |
| CIQTNF4 | 8e–05   | 1.7243 (1.31531, 2.26047) |
| DTX1    | 0.00093 | 1.44168 (1.16094, 1.79029) |
| GRID2IP | 0.01011 | 1.53138 (1.10672, 2.11898) |
| HOXD13  | 0.00354 | 1.15023 (1.04698, 1.26367) |
| M1AP    | 0.28923 | 0.83757 (0.60347, 1.16247) |
| NIN     | 0.08343 | 1.20467 (0.97569, 1.4874)  |
| PAQR6   | 1e–04   | 1.43385 (1.19635, 1.7849)  |
| RIMS3   | 0.03793 | 0.81789 (0.67648, 0.98886) |
| SEPTIN5 | 0.00178 | 5.16694 (1.84418, 14.47644) |
| SLC16A8 | <0.0001 | 1.71943 (1.39647, 2.11709) |
| SYT1    | 0.00473 | 1.23325 (1.0663, 1.42634)  |
| TNFRSF11A | 0.01191 | 0.82614 (0.71188, 0.95874) |
| TNNT1   | 0.00078 | 1.16233 (1.06469, 1.26893) |
| ZNF20   | 0.05909 | 0.43081 (0.1797, 1.03285)  |

| Multi_cox | P value | Hazard Ratio (95%CI) |
|-----------|---------|---------------------|
| ALPG      | 0.00313 | 1.15777 (1.05055, 1.27593) |
| CIQTNF4   | 0.06563 | 1.38167 (0.9793, 1.94935)  |
| DTX1      | 0.02048 | 1.33836 (1.04598, 1.71246) |
| GRID2IP   | 0.53437 | 1.12189 (0.78054, 1.61251) |
| HOXD13    | 0.00752 | 1.13597 (1.03458, 1.24729) |
| M1AP      | 0.03000 | 0.62047 (0.40318, 0.95484) |
| NIN       | 0.00983 | 1.35375 (1.07566, 1.70373) |
| PAQR6     | 0.08918 | 1.20027 (0.97244, 1.48147) |
| RIMS3     | 0.00147 | 0.70765 (0.57184, 0.87572) |
| SEPTIN5   | 0.10000 | 3.07378 (0.80643, 11.71596) |
| SLC16A8   | 0.03533 | 1.34075 (1.02035, 1.76176) |
| SYT1      | 0.04251 | 1.17618 (1.0055, 1.37583)  |
| TNFRSF11A | 0.15623 | 0.88235 (0.74216, 1.04902) |
| TNNT1     | 0.04472 | 1.11706 (1.00261, 1.24457) |
| ZNF20     | 0.05153 | 0.44694 (0.19869, 1.00538) |

Figure 5: Continued.
and it was found that the 15 mRNAs, M1AP, CIQTNF4, SYT1, SEPTIN5, GRID2IP, PAQR6, NIN, DTX1, TNFRSF11 A, HOXD13, ZNF20, ALPG, RIMS3, SLC16A8, and TNN1, had the potential to be prognostic biomarkers in CRC (Figure 4(c)). In the KM survival curve, the median time of the two groups was 3.1 years, and the OS probability of the high-risk group was poor, and its HR was 3.175 (95% CI: 1.368–7.293), indicating that the model was a risk model (Figure 4(d)). In addition, the AUC values in the ROC curve were all greater than 0.7, suggesting a good prognostic prediction ability of the model (Figure 4(e)).

3.5. The Identification of mRNAs with Prognostic Value in CRC. To investigate the mRNAs with prognostic values in CRC, we performed univariate and multivariate Cox regressions on the above 15 DEmRNAs. Under the premise of \( P < 0.05 \), it was found that ALPG, DTX1, HOXD13, RIMS3, SLC16A8, SYT1, and TNNT1 had a close relationship with the prognosis of CRC patients (Figures 5(a) and 5(b)). Subsequently, a nomogram on these genes was designed to predict the 1-, 3-, and 5-year survival rates of CRC patients (Figure 5(c)). As shown in Figure 5(d), the different dots were relatively close to the calibration curve, indicating that the prognostic model had good predictive ability.

3.6. RIMS3 and SLC16A8 Were the Key mRNAs Related to CRC in \( \beta\)-Elemene Treatment. To further explore the exact mRNAs related to CRC in \( \beta\)-elemene treatment, we detected the expressions of the 7 prognostic mRNAs in CRC tumor and normal samples. After detection, it was found that RIMS3 was significantly increased in normal samples, while SLC16A8 was substantially upregulated in tumor samples (Figures 6(a) and 6(d)), which indicated that RIMS3 was a suppressor gene while SLC16A8 was an oncogene in CRC. In the OS and PFS analyses on them, low expression of RIMS3 represented a poor survival rate, while low expression of SLC16A8 represented a relatively good survival rate (Figures 6(b), 6(c), 6(e), 6(f)).

4. Discussion

In recent years, the lncRNA-miRNA-mRNA network has been applied in the mechanism study of various diseases. For example, Li et al. found a novel lncRNA-miRNA-mRNA signature that predicted recurrence and disease-free survival in cervical cancer [19]. Cao et al. found through miR-206, lncRNA-RMRP increased bladder cancer development [20]. Besides, some researchers demonstrated lncRNA-CDC6 might act as a ceRNA to facilitate breast cancer development by sponging miRNA-215 [21]. In this study, we also tried to investigate the exact mechanism in \( \beta\)-elemene inhibiting CRC progression from the aspect of the lncRNA-miRNA-mRNA network.

Through deep sequencing, high-throughput screening, and microarray technology, many dysregulated miRNAs were found in cancer cells. Due to the tissue specificity of miRNA regulation, miRNAs have much potential to be biomarkers in cancer diagnosis, treatment, and prognosis [22]. In this study, we identified 1026 DElncRNAs, 6401 DEmiRNAs, and 36 DEmiRNAs in \( \beta\)-elemene-treated HCT116 cells using RNA sequencing. Then, these DERNAs were analyzed by functional analyses and PPI networks. Enrichment analysis showed that DElncRNAs were associated with the CCL18 signaling pathway. Ruixue Yuan et al. showed that high CCL18 levels can be an independent biomarker for predicting better survival in CRC patients [23]. The DEmiRNAs were related to the TGF-beta signaling pathwa

![Figure 5: The prognostic nomogram with prognostic mRNAs. (a)-(b) Univariate and multivariate Cox regression analyses. (c) The prognostic nomogram with prognostic mRNAs. (d) The dotted line is the ideal calibration curve of the nomogram.](https://doi.org/10.1155/2022/5896296)
**Figure 6:** RIMS3 and SLC16A8 were the key mRNAs related to CRC in β-elemene treatment. (a) RIMS3 significantly downregulated in CRC samples. (b)-(c) The Kaplan–Meier survival curve showing that lower expression levels of RIMS3 were significantly associated with shorter OS and PFS in CRC. (d) SLC16A8 upregulated in tumor samples. (e)-(f) The Kaplan–Meier survival curve showing that higher expression levels of RIMS3 were significantly associated with shorter OS and PFS in CRC. **P < 0.01, **** P < 0.0001.
pathway. TGF-beta signaling is one of the important cellular pathways that plays a key role in tissue maintenance. Nan et al. mentioned that LINC00941 plays an important role in metastatic CRC by activating the TGF-β/SMAD2/3 axis [24]. DEmRNAs are related to the leptin signaling pathway. Leptin is an activator of cell proliferation, an antiapoptotic molecule, and an inducer of cancer stem cells in many cell types. Studies have shown that the stringent binding affinity of leptin/Ob-R and the overexpression of leptin/Ob-R and its targets in cancer cells make it a unique drug target for the prevention and treatment of CRC, especially in obese colorectal patients [25]. In the PPI network, we selected the top RNAs in each group and observed their mutual relations, including miR-7109-3p, miR-4506, and miR-3182. At present, there are few reports on miR-7109-3p. One study highlights LINC00973-miR-7109-Siglec-15 function in the immune evasion of clear-cell renal cell carcinoma [26]. Nagy discovered miR-4506 was differentially expressed in adenoma compared to normal both in CRC tissue and plasma samples [27]. Moreover, it was found that the biological functions and potential mechanisms of miR-3182 were altered after Ganoderic acid treatment in CRC [28]. The 3 miRNAs all have the potential to be clinical biomarkers in CRC.

Besides, we focused on the mRNA associated with β-elemene and CRC. Through LASSO, risk score evaluation, and Cox analyses, 7 prognostic mRNAs, ALPG, DTX1, HOXD13, RIMS3, SLC16A8, SYT1, and TNNT1, were identified and applied to design the predictive nomogram for CRC prognosis, and the nomogram proved to have a good prediction ability. In the previous research, few studies were conducted on these genes. In a study on TNNT1, researchers demonstrated that TNNT1, a target of miR-873, is related to CRC prognosis [29]. Herein, our findings show that the 7 mRNAs could be the prognostic biomarkers for CRC patients.

Furthermore, two key mRNAs related to CRC were identified by expression and KM analysis, namely, RIMS3 and SLC16A8. According to the public database, RIMS3 was a suppressor gene in CRC, while SLC16A8 was an oncogene in CRC. Regulating synaptic membrane exocytosis 3 (RIMS3) is supposed to enable transmembrane transporter binding activity and participate in the calcium ion-regulated exocytosis of neurotransmitters. Currently, it is suggested that RIMS3 is a gene related to autism. Functional investigations on RIMS3 variations like p.E177A deepen our understanding of synaptic proteins’ function in autism pathogenesis [30]. Additionally, solute carrier family 16 member 8 (SLC16A8), alias MCT3 and REMP, belongs to a family of proton-coupled monocarboxylate transporters regulating lactate transport across cell membranes [31]. The study of Klipfel L demonstrates the loss of transport function of the hypomorphic allele in the SLC16A8 gene and offers a methodological framework for the investigation of other SLC16A8 alleles linked to age-related macular degeneration [32]. Currently, there are no reports about these two genes in CRC development. Based on our study, we conclude that RIMS3 and SLC16A8 are the key mRNAs involved in the β-elemene treatment in CRC progression, which certainly reveals the inhibitory mechanism of β-elemene in CRC. The study still has limitations. First, the expression profiles given by differential expression need to be validated with clinical samples. Second, further experimental studies are required to confirm the function of the IncRNA-miRNA-mRNA network in the inhibition of CRC progression by β-elemene.

To sum up, this study reveals the IncRNA-miRNA-mRNA network in the inhibitory function of β-elemene in CRC. These identified differentially expressed mRNAs (RIMS3 and SLC16A8) and miRNAs (miR-7109-3p, miR-4506, and miR-3182) all could be promising clinical biomarkers or targets in CRC diagnosis, treatment, and prognosis.

Data Availability

The datasets used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was funded by the Natural Science Foundation of Anhui Province (2008085QH388) and Clinical Research Project of the Anhui University of Chinese Medicine (2021efylc02).

References

[1] N. Akimoto, T. Ugai, R. Zhong et al., “Rising incidence of early-onset colorectal cancer - a call to action,” Nature Reviews Clinical Oncology, vol. 18, no. 4, pp. 230–243, 2021.
[2] N. Keum and E. Giovannucci, “Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies,” Nature Reviews Gastroenterology & Hepatology, vol. 16, no. 12, pp. 713–732, 2019.
[3] T. Sawicki, M. Ruszkowska, A. Danielewicz, E. Niedzwiedzka, T. Arlukowicz, and K. E. Przybylowicz, “A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis,” Cancers, vol. 13, no. 9, p. 2025, 2021.
[4] S. K. P. John, S. George, J. N. Primrose, and J. B. J. Fozard, “Symptoms and signs in patients with colorectal cancer,” Colorectal Disease, vol. 13, no. 1, pp. 17–25, 2011.
[5] F. Baidoun, K. Elshiwly, Y. Elkeraiet al., “Colorectal cancer epidemiology: recent trends and impact on outcomes,” Current Drug Targets, vol. 22, no. 9, pp. 998–1009, 2021.
[6] S. Ye, L. Yang, X. Zhao, W. Song, W. Wang, and S. Zheng, “Bioinformatics method to predict two regulation mechanisms: TF–miRNA–mRNA and IncRNA–miRNA–mRNA in pancreatic cancer,” Cell Biochemistry and Biophysics, vol. 70, no. 3, pp. 1849–1858, 2014.
[7] Y. Zhang, Y. Li, Q. Wang et al., “Identification of an IncRNA-miRNA-mRNA interaction mechanism in breast cancer based on bioinformatic analysis,” Molecular Medicine Reports, vol. 16, no. 4, pp. 5113–5120, 2017.
[8] R.-S. Zhou, E. X. Zhang, Q. F. Sun et al., “Integrated analysis of IncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue,” BMC Cancer, vol. 19, no. 1, p. 779, 2019.
[9] A. Link and J. Kupcinskas, “MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: current insights and future perspectives,” *World Journal of Gastroenterology*, vol. 24, no. 30, pp. 3313–3329, 2018.

[10] P. M. Pereira, J. P. Marques, A. R. Soares, L. Carreto, and M. A. S. Santos, “MicroRNA expression variability in human cervical tissues,” *PloS One*, vol. 5, no. 7, Article ID e11780, 2010.

[11] A. Fonseca, S. V. Ramalhete, A. Mestre et al., “Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression,” *Aging (Albany NY)*, vol. 13, no. 18, pp. 21991–22029, 2021.

[12] Y. Feng, C. Li, S. Liu et al., “β-Elemene restrains PTEN mRNA degradation to restrain the growth of lung cancer cells via METTL3-mediated N(6) methyladenosine modification,” *Journal of Oncology*, vol. 2021, pp. 1–11, 2022.

[13] Y. Pan, W. Wang, S. Huang et al., “Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation,” *Journal of Cellular and Molecular Medicine*, vol. 23, no. 10, pp. 6846–6858, 2019.

[14] P. Chen, X. Li, R. Zhang et al., “Combative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation,” *Theranostics*, vol. 10, no. 11, pp. 5107–5119, 2020.

[15] X. Zhang, Y. Chen, J. Yao et al., “β-elemene combined with temozolomide in treatment of brain glioma,” *Biochemistry and Biophysics Reports*, vol. 28, Article ID 101144, 2021.

[16] S. Zhang and W. Guo, “β-Elemene enhances the sensitivity of osteosarcoma cells to doxorubicin via downregulation of peroxiredoxin-1,” *OncoTargets and Therapy*, vol. 14, pp. 3599–3609, 2021.

[17] W. Zhan, H. Li, Y. Guo, G. Du, Y. Wu, and D. Zhang, “Construction of biocompatible dual-drug loaded complicated nanoparticles for in vivo improvement of synergistic chemotherapy in esophageal cancer,” *Frontiers in Oncology*, vol. 10, p. 622, 2020.

[18] G. Y. Wang. *The Study on the Effect and Mechanism of β-elemene in Colorectal Cancer*, Anhui Medical University, Hefei, China, 2018.

[19] M. Li, X. Tian, H. Guo et al., “A novel IncRNA-miRNA-miRNA signature predicts recurrence and disease-free survival in cervical cancer,” *Brazilian Journal of Medical and Biological Research*, vol. 54, no. 11, Article ID e11592, 2021.

[20] H. L. Cao, Z. J. Liu, P. L. Huang, Y. L. Yue, and J. N. Xi, “IncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206,” *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 3, pp. 1012–1021, 2019.

[21] X. Kong, Y. Duan, Y. Sang et al., “IncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215,” *Journal of Cellular Physiology*, vol. 234, no. 6, pp. 9105–9117, 2019.

[22] Y. Xu, R. Geng, F. Yuan, Q. Sun, B. Liu, and Q. Chen, “Identification of differentially expressed key genes between glioblastoma and low-grade glioma by bioinformatics analysis,” *PeerJ*, vol. 7, Article ID e6560, 2019.

[23] R. Yuan, Y. Chen, X. He et al., “CCL18 as an independent favorable prognostic biomarker in patients with colorectal cancer,” *Journal of Surgical Research*, vol. 183, no. 1, pp. 163–169, 2013.

[24] N. Wu, M. Jiang, H. Liu et al., “LINC00941 promotes CRC metastasis through preventing SMAD4 protein degradation and activating the TGF-β/SMAD2/3 signaling pathway,” *Cell Death & Differentiation*, vol. 28, no. 1, pp. 219–232, 2021.

[25] W. Zhou, Y. Tian, H. Gong, S. Guo, and C. Luo, “Oncogenic role and therapeutic target of leptin signaling in colorectal cancer,” *Expert Opinion on Therapeutic Targets*, vol. 18, no. 8, pp. 961–971, 2014.

[26] D. S. Karpov, P. V. Spirin, A. O. Zheltukhin et al., “LINC00973 induces proliferation arrest of drug-treated cancer cells by preventing p21 degradation,” *International Journal of Molecular Sciences*, vol. 21, no. 21, p. 8322, 2020.

[27] Z. B. Nagy, B. Wichmann, A. Kalmar et al., “Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens,” *Clinical Epigenetics*, vol. 9, no. 1, p. 22, 2017.

[28] N. Chen, G. Wan, and X. Zeng, “Integrated whole-transcriptome profiling and bioinformatics analysis of the polypathological effects of ganoderic acid me in colorectal cancer treatment,” *Frontiers in Oncology*, vol. 12, Article ID 833375, 2022.

[29] Y. Chen, J. Wang, D. Wang et al., “TNNT1, negatively regulated by miR-873, promotes the progression of colorectal cancer,” *The Journal of Gene Medicine*, vol. 22, no. 2, Article ID e3152, 2020.

[30] R. A. Kumar, J. Sudi, T. D. Babatz et al., “A de novo 1p34.2 microdeletion identifies the synaptic vesicle gene RIM3 as a novel candidate for autism,” *Journal of Medical Genetics*, vol. 47, no. 2, pp. 81–90, 2010.

[31] H. Yoon, L. A. Donoso, and N. J. Philp, “Cloning of the human monocarboxylate transporter MCT3 gene: localization to chromosome 22q12.3-q13.2,” *Genomics*, vol. 60, no. 3, pp. 366–370, 1999.

[32] L. Klipfel, M. Cordonnier, L. Thiebaut et al., “A splice variant in SLC16A8 gene leads to lactate transport deficit in human iPS cell-derived retinal pigment epithelial cells,” *Cells*, vol. 10, no. 1, p. 179, 2021.